<?xml version="1.0" encoding="utf-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005">
<channel xmlns:cfi="http://www.microsoft.com/schemas/rss/core/2005/internal" cfi:lastdownloaderror="None">
<title cf:type="text"><![CDATA[Progress in Biochemistry and Biophysics -->Perspectives]]></title>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[An Insight of D-Ribose Metabolic Imbalance in Type 2 Diabetes Mellitus]]></title>
<link><![CDATA[http://www.pibb.ac.cn/pibben/article/abstract/20150044]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[An Insight of D-Ribose Metabolic Imbalance in Type 2 Diabetes Mellitus]]></description>
<pubDate>2015/4/24 0:00:00</pubDate>
<category><![CDATA[Perspectives]]></category>
<author><![CDATA[SU Tao and HE Rong-Qiao]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>SU Tao and HE Rong-Qiao</atom:name>
</atom:author>
<guid><![CDATA[http://www.pibb.ac.cn/pibben/article/abstract/20150044]]></guid><cfi:id>6</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[The Role of Adipokine Chemerin in Pregnancy Complications]]></title>
<link><![CDATA[http://www.pibb.ac.cn/pibben/article/abstract/20150138]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Pregnancy complications, such as, recurrent pregnancy loss, gestational diabetes mellitus, preterm labor, intrauterine growth restriction and preeclampsia, greatly impaired the health and quality of daily life of pregnant women and neonatal. However, the etiology of most of the pregnancy complications is still unclear. Recently, appearing in younger population and increasing incidence of lipid and carbohydrate metabolism disorders, such as obesity and diabetes, will lead to increasing reproductive health issues in this population. Studies have shown that the pregnancy complications are correlated with lipid and carbohydrate metabolism disorders and hypertension, but the internal links are still unclear. Adipokine Chemerin was involved with both of the metabolism disorders and hypertension, so as abnormal expressed in pregnancy complications. However, whether it is the cause of pathogenesis of pregnancy complications or not, is still unclear. To address the possible etiological role of Chemerin with pregnancy complications, we summarized the research advance of Chemerin on pregnancy and pregnancy complications studies and combined with the findings in the pathogenesis of Chemerin with metabolism disorders and hypertension. This review will provide new ideas and directions for pregnancy complication investigations.]]></description>
<pubDate>2015/10/21 0:00:00</pubDate>
<category><![CDATA[Perspectives]]></category>
<author><![CDATA[ZHANG Qing-Qing, FAN Xiu-Jun and ZHANG JIan]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>ZHANG Qing-Qing, FAN Xiu-Jun and ZHANG JIan</atom:name>
</atom:author>
<guid><![CDATA[http://www.pibb.ac.cn/pibben/article/abstract/20150138]]></guid><cfi:id>5</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[CRISPR/Cas9 System: an Important Tool for Brain and Cognitive Science]]></title>
<link><![CDATA[http://www.pibb.ac.cn/pibben/article/abstract/20170237]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[How the brain works is one of the most mysterious yet challenging problems in life sciences. Understanding the molecular and neural basis of cognition and memory is expected to not only aid the exploration of the pathogenesis of neurological and neuropsychiatric disorders but also provide the fundamental principles for brain-inspired intelligence. Various neural technologies are continuously developed to provide tools for resolving this ultimate biological problem. Such technologies include molecular genetic tools (particularly genetically encoded calcium indicators and viral trans-synaptic labeling vectors) that images neural circuit activities and neuro-anatomy.  CRISPR/Cas9 (Clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) system is a powerful molecular genetic tool that has revolutionized various scientific fields, especially genome editing, gene expression control, cellular imaging, and molecular tracing. In this review, we discuss the applications and limitations of CRISPR/Cas9 technology in neuroscience and provide possible directions and strategies for the advancement of CRISPR/Cas9 technology in studying the neural basis of cognition and memory.]]></description>
<pubDate>2017/9/21 0:00:00</pubDate>
<category><![CDATA[Perspectives]]></category>
<author><![CDATA[WANG Hao, YAN Yan, JIAO Ren-Jie, MIN Lu, ZHU Ling-Yun and ZHANG Dong-Yi]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>WANG Hao, YAN Yan, JIAO Ren-Jie, MIN Lu, ZHU Ling-Yun and ZHANG Dong-Yi</atom:name>
</atom:author>
<guid><![CDATA[http://www.pibb.ac.cn/pibben/article/abstract/20170237]]></guid><cfi:id>4</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Tumor Cell Dormancy: How It Performs in Drug Resistance and Relapse]]></title>
<link><![CDATA[http://www.pibb.ac.cn/pibben/article/abstract/20170389]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Despite progresses achieved in the therapy of tumors, the prognosis of patients is still limited by reccurence of residual tumor cells. Cancer cell dormancy plays a pivotal role in cancer relapse and drug resistance. In recent years, tumor cells undergoing EMT(epithelial-mesenchymal transition), CSCs(cancer stem cells) and CTCs(circulating tumor cells) are proved to share some common characteristics and show a cell cycle arrest phenotype. Thus, understanding the dormant stage of tumor cells could facilitate us in discovering ways to accelerate the development of tumor therapy and prevent its reccurence. In this review, we summarize the specific process of tumor cell dormancy induced by pharmacotherapy, and consider that dormancy is an initiative response rather than a passive defense to cytotoxicity. Besides, we probe into the mechanisms of tumor cell dormancy-mediated drug resistance, anticipating paving a way to target dormant tumor cells and result in better clinical outcomes.]]></description>
<pubDate>2018/4/18 0:00:00</pubDate>
<category><![CDATA[Perspectives]]></category>
<author><![CDATA[DAI Ya-Fei and XIANG Juan-Juan]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>DAI Ya-Fei and XIANG Juan-Juan</atom:name>
</atom:author>
<guid><![CDATA[http://www.pibb.ac.cn/pibben/article/abstract/20170389]]></guid><cfi:id>3</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[The Concept of an Advanced Version of Western Blot (WB 2.0) and Its Perspectives]]></title>
<link><![CDATA[http://www.pibb.ac.cn/pibben/article/abstract/20190140]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Western blot (WB) is widely used to investigate the expression profiling for target proteins，which depends on the specific binding with antibodies and it is a fundamental technique in basic and application field of life science. However, traditional WB technique involves many manual steps, it is difficult to set up standard operational protocols. In most of the cases, it is used only within same WB analysis for the abundance investigation of target proteins qualitatively or relative quantitatively, while problematic to carry out comparison among different laboratories. In the current paper, after a summarized historical review of WB development, the concept of advance version of WB (WB 2.0) was proposed. The key components for the design and practical steps including digitalization, standardization, automation, micro-quantification, high through-put, reference-based normalization and database establishment were presented. In perspective, the application of WB 2.0 will activate the establishment of a public accessible protein expression database, which will be another supporting platform for life science succeeding the recognized genome and transcriptome databases.]]></description>
<pubDate>2019/12/20 16:03:04</pubDate>
<category><![CDATA[Perspectives]]></category>
<author><![CDATA[ZHANG Liu,SHI Jia-Nan and LIU Guo-Zhen]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>ZHANG Liu,SHI Jia-Nan and LIU Guo-Zhen</atom:name>
</atom:author>
<guid><![CDATA[http://www.pibb.ac.cn/pibben/article/abstract/20190140]]></guid><cfi:id>2</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Approval of The First-Ever RNAi Therapeutics and Its Technological Development History]]></title>
<link><![CDATA[http://www.pibb.ac.cn/pibben/article/abstract/20180249]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Recently, the United States Food and Drug Administration (FDA) and the European Commission (EC) approved ONPATTRO? (Patisiran) lipid complex injection, an RNA interference (RNAi) therapeutic developed by Alnylam Pharmaceuticals, Inc., for the treatment of the polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults. ONPATTRO is the first approved RNAi therapeutics all over the world, indicating the whole development processes have been well established. It also means a novel form of drug molecule comes to beside from bench, following the small molecules and monoclonal antibodies. Based on this milestone achievement, the basic information of the drug and indication, the mechanism and properties of RNAi therapeutics, its complicated development history, as well as the latest advances of delivery and modification technologies, were thoroughly reviewed and discussed in this paper, which provides a rough picture for ONPATTRO and RNAi therapy.]]></description>
<pubDate>2019/3/25 15:05:32</pubDate>
<category><![CDATA[Perspectives]]></category>
<author><![CDATA[HUANG Yuan-Yu]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>HUANG Yuan-Yu</atom:name>
</atom:author>
<guid><![CDATA[http://www.pibb.ac.cn/pibben/article/abstract/20180249]]></guid><cfi:id>1</cfi:id><cfi:read>true</cfi:read></item>
</channel>
</rss>